Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200¿500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Background:
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety of IPE in patients (N = 702) with residual high fasting TG levels (>=200 and =40 and

Source: Cardiovascular Diabetology - July 9, 2013 Category: Cardiology Authors: Eliot BrintonChristie BallantyneHarold BaysJohn KasteleinRene BraeckmanParesh Soni Source Type: research